Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Urogen Pharma Ltd (NQ: URGN )

12.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Urogen Pharma Ltd

< Previous 1 2 3 Next >
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q2 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
Via Benzinga
Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
The company is working on a treatment for non-muscle invasive bladder cancer. 
Via Investor's Business Daily
Earnings Outlook For UroGen Pharma
Via Benzinga
Recap: UroGen Pharma Q3 Earnings
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Preview: UroGen Pharma's Earnings
Via Benzinga
The Latest Analyst Ratings for UroGen Pharma
Via Benzinga
Where UroGen Pharma Stands With Analysts
Via Benzinga
Recap: UroGen Pharma Q1 Earnings
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
UroGen Pharma Earnings Preview
Via Benzinga
UroGen Pharma's Return On Capital Employed Overview
Via Benzinga
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy to UN against ceasefire. Investigations into civilian casualties & use of... 
Via Benzinga
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
Discover how Cathie Wood's ARK Israel Innovative Tech ETF responds to the Israel-Hamas conflict. Explore its portfolio performance and top Israeli stocks to watch amidst geopolitical turmoil. 
Via Benzinga
Topics ETFs
$10 Trillion Added In Market Cap; 2023’s Best And Worst Through July
The US stock market has now seen an increase in market cap of roughly $10 trillion from its bear market low last October through the end of July 2023. 
Via Talk Markets
Why Shares of UroGen Pharma Jumped Friday
The company released positive top-line results for two studies for a bladder cancer treatment. 
Via The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
Why NICE Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million definitive agreement for Bruker to acquire PhenomeX in an all-cash... 
Via Benzinga
Enphase Energy, Sanofi, Ford And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Why UroGen Pharma Stock Is Gaining Today?
UroGen Pharma Ltd (NASDAQ: URGN) shares are surging after the company released topline data from its Phase 3 trials ATLAS and ENVISION studying UGN-102 (mitomycin) for intravesical solution in patients... 
Via Benzinga
Earnings Scheduled For August 10, 2023
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million. 
Via Benzinga
Earnings Scheduled For May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its... 
Via Benzinga
Earnings Scheduled For March 16, 2023
Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 8, 2023
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.